Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

of the call will be available until 9:29 p.m. on October 22, 2007.

This press release contains forward-looking statements, including statements about timelines for obtaining and presenting clinical trial data, the expected efficacy of alemtuzumab in MS and its comparison to current market products, the possibility of approval of alemtuzumab in MS, and the continued enrollment of patients in related MS clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, that actual results of the clinical trials demonstrate safety and efficacy comparable to the data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme and Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. Rebif(R) is a registered trademark of EMD Serono, Inc.

Genzyme's press releases and other comp
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... FORT MYERS, Fla. , Jan. 23, 2015  Today ... approval of Novartis, Bexsero® for the prevention of ... to 25. Bexsero and Pfizer,s vaccine Trumenba®, which received ... in helping prevent this devastating disease. ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... , SHANGHAI , May 11 /PRNewswire-Asia/ -- ... Hao Zhou as Chief Financial Officer,effective immediately. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) , ... Mr. Zhou joined the company in May 2009 ...
... Dynatronics Corporation (Nasdaq: DYNT ) plans to release financial results for its ... 17, 2010 .   , , , ... conference call for investors later that day at 1:30 p.m. ET to ... use passcode: 9921511. , , , ...
Cached Medicine Technology:WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer 2WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer 3
(Date:1/22/2015)... The City of West Hollywood hosted a news ... the 42nd anniversary of the Supreme Court decision Roe v. Wade, ... years since the Roe vs. Wade decision and the fight to ... ever,” said City of West Hollywood Councilmember Abbe Land. “We need ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... , WEDNESDAY, Aug. 25 (HealthDay News) -- Two of ... a connection, with new research suggesting that having insulin resistance ... brain plaques associated with Alzheimer,s disease. After adjusting for ... the highest levels of fasting insulin had nearly six times ...
... has filed an Investigational New Drug (IND) application with ... begin a Phase I safety clinical trial for chronic ... This multicenter Phase I safety trial will enroll a ... patients, with an American Spinal Injury Association (ASIA) Grade ...
... WEDNESDAY, Aug. 25 (HealthDay News) -- Cholesterol-lowering statins could ... among patients who are deemed to have an "intermediate ... The finding specifically applies to those men and women ... of a protein linked to inflammation (the so-called high ...
... Mayo Clinic discovered several years ago that laboratory samples of ... help them find new treatments for this lethal disease were ... evident that the situation in their lab was common throughout ... were supposed to originate from patients with this rare thyroid ...
... immunity to mumps is high in the United ... improved to prevent future outbreaks, according to a ... in the September 1, 2010 issue of The ... found in most parts of the worldcan cause ...
... 24, 2010) What does it feel like to return ... it has been difficult during astronaut training to realistically simulate ... Dr. Steven Moore leads a research group that has ... the sensory and mobility disturbances commonly experienced by astronauts after ...
Cached Medicine News:Health News:Link Between Diabetes, Alzheimer's Disease Strengthened 2Health News:Link Between Diabetes, Alzheimer's Disease Strengthened 3Health News:Link Between Diabetes, Alzheimer's Disease Strengthened 4Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 2Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 3Health News:Study Suggests Statins Could Help Some With Normal Cholesterol 2Health News:Study Suggests Statins Could Help Some With Normal Cholesterol 3Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 2Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 3Health News:Mumps vaccine coverage should be improved, study finds 2Health News:System uses electrical trickery on the brain to induce realistic spaceflight effects 2Health News:System uses electrical trickery on the brain to induce realistic spaceflight effects 3
The double beveled oblique blade provides a true, straight incision. Penetrating through Bowman's and Descemet's membranes without inducing corneal distortion. No need to "Dimple Down"....
... The DioLite 532 laser is indicated ... pigmented skin lesions such as telangiectasia, ... wine stains, lentigines, dermatosis papulosis nigra ... offers unsurpassed reliability, a selection of ...
... Fingertips a comprehensive pocket-sized reference ... information on the evaluation and management of ... people. Updated annually. The complete content is ... versions for Pocket PC- and Palm-based PDAs ...
... is a fully integrated custom assay service that ... upon the assay of interest, the customer simply ... and we will provide a protocol and a ... the test in the laboratory. This will help ...
Medicine Products: